Three Ways Patients Will Pay the Price

If the Supreme Court upholds the Fifth Circuit Opinion in Alliance for Hippocratic Medicine v FDA, the integrity of the FDA is at risk.

**Three Ways Patients Will Pay the Price**

**Undercuts FDA’s Role Ensuring Public Health and Safety**
- Judges decide the science and what medications FDA can approve, instead of relying on FDA’s expertise and oversight of medications and devices.
- Casts uncertainty over every FDA approval.
- Invites spurious lawsuits years or decades after approval.

**Destabilizes Investment in New Medications, Therapies, and Devices**
- Frivolous litigation creates costly burdens and unnecessary risks for pharmaceutical companies.
- Less investment = less research and development = fewer or more costly medications.

**Harms Patient Health and Access to Care**
- Standards of care should be guided by scientific expertise, not dictated by judges which could result in:
  - Outdated dosing regimens = substandard care for patients.
  - Fewer drug approvals = less investment in drug development = fewer or more costly medications.
  - Lower commitment to public health = violation of patient and provider trust in medications.

More highlights from amicus briefs filed by pharmaceutical companies, patient and provider and patient advocacy groups and former FDA commissioners available at emaaproject.org/briefs